Use of Allosteric Targets in the Discovery of Safer Drugs

  title={Use of Allosteric Targets in the Discovery of Safer Drugs},
  author={Ashok Kumar Grover},
  journal={Medical Principles and Practice},
  pages={418 - 426}
  • A. Grover
  • Published 23 May 2013
  • Biology, Chemistry, Medicine
  • Medical Principles and Practice
The need for drugs with fewer side effects cannot be overemphasized. Today, most drugs modify the actions of enzymes, receptors, transporters and other molecules by directly binding to their active (orthosteric) sites. However, orthosteric site configuration is similar in several proteins performing related functions and this leads to a lower specificity of a drug for the desired protein. Consequently, such drugs may have adverse side effects. A new basis of drug discovery is emerging based on… 

Figures from this paper

Emerging Computational Methods for the Rational Discovery of Allosteric Drugs

Algorithms that predict allosteric sites based on sequence data and molecular dynamics simulations are reviewed, tools that assess the druggability of these pockets are described, and how Markov state models and topology analyses provide insight into the relationship between protein dynamics andallosteric drug binding are discussed.

Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor

This paper reviews and summarizes the complex pharmacological profiles of each class of CB1 allosteric modulators, the development of new classes of CB 1 allosterics modulators and the results from in vivo assessments of their therapeutic value.

Current Trends in GPCR Allostery.

This chapter discusses GPCR crystal structures solved with allosteric ligands, advantages ofallosteric drugs, and allosterics drugs which are in clinical use or trials.

Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor

The feasibility of discovering PAMs that can convert an armamentarium of potent but nonselective G-protein–coupled receptor (GPCR) antagonist drugs into subtype-selective reagents, thus reducing their off-target effects is supported.

Challenges in the Discovery and Optimization of mGlu2/4 Heterodimer Positive Allosteric Modulators

The challenges in the discovery and optimization of mGlu2/4 heterodimer Positive Allosteric Modulators exemplified the challenges in developing allosteric ligands forheterodimeric receptors and required the team to develop a new screening cascade paradigm.

Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.

Findings indicated that the structural characteristics of RM-493 may allow for enhanced receptor-ligand interactions, particularly through those with the putative allosteric binding sites, which facilitated the ligand to stabilize the active state of native and mutant MC4Rs to maintain reasonably high affinity and potency.

Allosteric binding sites in Rab11 for potential drug candidates

It is shown that these binding sites may allosterically regulate Rab11, as these sites communicate with switch 2 region that binds to GTP/GDP, which is similar to two allosteric pockets in Ras that were discovered previously.

Ligand-Targeted Drug Delivery.

Criteria that must be met during design of ligand-targeted drugs (LTDs) to achieve the required therapeutic potency with minimal toxicity are summarized.



Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels

This review will consider select examples of extracellular drugable targets and focus on the GPCRs and ion channels highlighting the corticotropin releasing factor type 1 and γ-aminobutyric acid receptors, and the CaV2.2 voltage-gated ion channel.

Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.

Designing small synthetic compounds allosterically interacting with the proteasome represents a novel approach that has enormous potential for the treatment of a wide range of diseases.

Identification of allosteric-activating drug leads for human liver pyruvate kinase.

  • A. Fenton
  • Biology, Medicine
    Methods in molecular biology
  • 2012
Using hL-PYK, the potential of drug library screens to identify allosteric-activator drug leads is demonstrated and one potential mechanism to counteract hyperglycemia is identified.

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

There have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function that provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

In the past 10 years major advances have been achieved in the discovery of allosteric ligands that possess much greater selectivity for individual mAChR subtypes when compared to previously developed orthosteric agents.

Strategies in the rational drug design.

Various strategies applied for systems which include: (i) absence of knowledge of the receptor active site; (ii) the knowledge of a homology model of a receptor, (iii) theknowledge of the experimentally determined coordinates of the active site of the protein in absence and (iv) the presence of the ligand will be analyzed.

Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1.

A fluorescent method using the ATP analog TNP-ATP is described that allows evaluating the allosteric conformational changes at the ATP-binding site of PDK1 triggered by small compounds binding to the PIF-pocket.

Molecular Motions as a Drug Target: Mechanistic Simulations of Anthrax Toxin Edema Factor Function Led to the Discovery of Novel Allosteric Inhibitors

Amongst 18 compounds selected in silico and tested in an enzymatic assay, 6 thiophen ureidoacid derivatives formed a new family of EF allosteric inhibitors with IC50 as low as 2 micromolars.

mGlu5 negative allosteric modulators: a patent review (2010 – 2012)

  • K. Emmitte
  • Biology
    Expert opinion on therapeutic patents
  • 2013
The design and development of small molecule negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) has been an area of intense interest for over a decade and optimism remains that a drug will emerge from this therapeutic class.